Evidence map›Paper›PMID 33100093›Full record

ArticleInternational journal of immunopathology and pharmacology

KCNQ1OT1 accelerates gastric cancer progression via miR-4319/DRAM2 axis.

Jijun Wang, Fan Wu, Yaoyao Li, Lei Pang, Xiaohong Wang, Guimei Kong, Tong Zhang, Duonan Yu

RetractedOpen access · goldAbstract readRetracted Publication
In one paragraph

Article in International journal of immunopathology and pharmacology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It has been retracted, and should not be counted. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
0.7field-weighted citation impact, top 35% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 10 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Article
  6. Review
  7. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Jijun WangInstitute of Translational Medicine, Medical College, Yangzhou University, Yangzhou, China.
Fan WuInstitute of Translational Medicine, Medical College, Yangzhou University, Yangzhou, China.
Yaoyao LiDepartment of Gastroenterology, Affiliated Hospital of Yangzhou University, Yangzhou University, Yangzhou, China.
Lei PangDepartment of Gastroenterology, Affiliated Hospital of Yangzhou University, Yangzhou University, Yangzhou, China.
Xiaohong WangInstitute of Translational Medicine, Medical College, Yangzhou University, Yangzhou, China.
Guimei KongDepartment of Laboratory Medicine, Medical College, Yangzhou University, Yangzhou, China.
Tong ZhangXinghua People's Hospital, Yangzhou University, Xinghua, China.
Duonan YuInstitute of Translational Medicine, Medical College, Yangzhou University, Yangzhou, China.ORCID https://orcid.org/0000-0002-8317-7017
Yangzhou University · CNXintai People's Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionThis work was to explore the connection of KCNQ1 opposite strand/antisense transcript 1 (KCNQ1OT1) and microRNA-4319 (miR-4319), and to investigate the associated underlying mechanisms in gastric cancer (GC) progression.

methodsQuantitative real-time PCR was performed to measure KCNQ1OT1, miR-4319 and DNA-damage regulated autophagy modulator 2 (DRAM2) expression levels in GC cells. Moreover, expression level of KCNQ1OT1 and DRAM2 in GC tissues was analyzed at ENCORI website (http://starbase.sysu.edu.cn/index.php). Cell proliferation, colony formation assay and flow cytometry assays were performed to analyze effects of KCNQ1OT1, miR-4319 and DRAM2 on cell growth and death. Dual-luciferase activity reporter assay and RNA immunoprecipitation assay was conducted to verify the interactions of KCNQ1OT1 or DRAM2 and miR-4319. RESULTS AND

conclusionWe found KCNQ1OT1 level was increased in tumor tissues and cells. Force the expression of KCNQ1OT1 promotes, while knockdown KCNQ1OT1 inhibits GC cell growth. Further studies indicated miR-4319 functioned as a bridge between KCNQ1OT1 and DRAM2. Finally, we showed KCNQ1OT1/miR-4319/DRAM2 axis regulates GC cell growth in vitro and in vivo. lncRNA KCNQ1OT1 promotes GC progression by sponging miR-4319 to upregulate DRAM2, indicating KCNQ1OT1 might be a promising target for GC treatment.

Indexed as

ApoptosisCell Line, TumorCell ProliferationDisease ProgressionGene Expression Regulation, NeoplasticHumansMembrane ProteinsMicroRNAsPotassium Channels, Voltage-GatedSignal TransductionStomach NeoplasmsDRAM2 protein, humanKCNQ1OT1 long non-coding RNA, humanMembrane ProteinsMicroRNAsMIRN4319 microRNA, humanPotassium Channels, Voltage-Gatedapoptosisgastric cancerLncRNA KCNQ1OT1miR-4319/DRAM2 axisproliferation

Identifiers

PMID33100093
PMCPMC7786410
OpenAlexW3093856995

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.